Expression pattern of the CXCL12/CXCR4-CXCR7 trio in Kaposi sarcoma skin lesions

Desnoyer, Aude; Dupin, Nicolas; Assoumou, Lambert; Carlotti, A.; Gaudin, Françoise; Deback, Claire; Peytavin, Gilles; Marcelin, Anne‐Geneviève; Balabanian, Karl; Pourcher, Valérie

doi:10.1111/bjd.14748

Cited by 15 publications

(11 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CXCR7 has been implicated in the growth, metastasis, and survival of tumor cell lines such as prostate [16], glioma [12], bladder [50], pancreatic [37], Kaposi sarcoma [51], ovarian [38], cervical [52], colon [39], uterine [40], kidney [40], liver [40], stomach [40], lung and breast [41] as well as hepatocellular carcinoma [3]. CXCR7 is present on tumor endothelial, glioma and microglial cells, and is often colocalized with CXCL12 [12].…”

Section: The Role Of Cxcr7 In Cancersmentioning

confidence: 99%

Advances in CXCR7 Modulators

Lounsbury

2020

Pharmaceuticals

View full text Add to dashboard Cite

CXC chemokine receptor 7 (CXCR7) is a G-protein-coupled receptor that signals through the β-arrestin pathway. Its ligands include interferon-inducible T cell α chemoattractant (CXCL11) and stromal cell-derived factor-1 (CXCL12). It interacts with CXCR4, and the two are associated with various cancers, as well as other disease states such as coronary artery disease, stroke, inflammation and human immunodeficiency virus (HIV). Antibodies and small interfering RNA (siRNA) have shown the utility of antagonists of CXCR7 in these disease states. Although some small molecules were initially reported as antagonists due to their displayed activity, many function as agonists while still producing the desired pharmacologic effects. A potential reason for this contradiction is that effects may be due to elevated extracellular CXCL12 levels.

show abstract

Section: The Role Of Cxcr7 In Cancersmentioning

confidence: 99%

Advances in CXCR7 Modulators

Lounsbury

2020

Pharmaceuticals

View full text Add to dashboard Cite

show abstract

“…12 Specifically, CXCL12 is known to drive lymphocyte and macrophage chemotaxis 13,14 in pathophysiological settings of several systems. 15,[17][18][19][20][21][22][23][24][25][26][27] A gradient of CXCL12 is established by secretion from inflammatory environments. This process is known to promote tumour growth and metastasis in at least 20 malignancies.…”

Section: Xcl12mentioning

confidence: 99%

“…15,16 Some examples of the pathophysiological involvement of CXCL12 are depicted and referenced in Table 2 and consist of cancer promotion, reproductive illness to periodontal disease. 15,[17][18][19][20][21][22][23][24][25][26][27] A gradient of CXCL12 is established by secretion from inflammatory environments. Over the past decade, the involvement of chemokines and their respective receptors has been successively elucidated.…”

Section: Xcl12mentioning

confidence: 99%

The CXL12/CXCR4/CXCR7 axis in female reproductive tract disease: Review

Krikun

2018

American J Rep Immunol

View full text Add to dashboard Cite

Initial studies on the chemokine stromal derived factor 1 (now referred to as CXCL12) were proposed to be enhanced in several diseases including those which affect the female reproductive tract. These include endometriosis, Asherman's syndrome, endometrial cancers, and ovarian cancers. Additionally, recent studies from our laboratory suggest that CXCL12 signaling is involved in leiomyomas (fibroids). These diseases present an inflammatory/hypoxic environment which further promotes pathology. At first, studies focused on signaling by CXCL12 via its well-known receptor, CXCR4. However, the discovery of CXCR7 as another receptor for CXCL12 with rather high binding affinity and recent reports about its involvement in endometrial disease and cancer progression has questioned the potential of "selective blockade"' of CXCR4 to treat these ailments. This review will focus on the signaling and effects of the potent chemokine CXCL12, and its long-known G protein-coupled receptor CXCR4, as well as the alternate receptor CXCR7 on the female reproductive tract and related diseases such as endometriosis, Asherman's syndrome, leiomyomas, endometrial cancer, and ovarian cancer. Although several other mechanisms are inherent to these diseases such as gene mutations, differential expression of miRNAs and epigenetics, for this review, we will focus on the CXCL12/CXCR4/CXCR7 axis as a novel target.

show abstract

“…Kaposi's sarcoma (KS) remains a prevalent neoplasia worldwide. This neoplasia is a multifactorial disease arising from the combined presence of human herpesvirus-8 (HHV-8), a microenvironment rich in particular cytokines and growth factors, and an immunosuppressed state (Desnoyer et al, 2016). Local therapies, namely topical treatments, allows clinicians to offer patients an alternative to surgery in cases where excision may be difficult.…”

mentioning

confidence: 99%